Skip to Main Content
TABLE 1

Clinical characteristics at the initial evaluation period in the subgroups according to the status of a 50% reduction of UAE

50% reductionNonreduction
n 93 123 
Sex (male/female) 56/37 85/38 
Age (years) 62 ± 8 61 ± 10 
Duration of diabetes (years) 14 ± 8 13 ± 9 
A1C (%) 7.5 ± 0.9 7.5 ± 1.0 
Blood pressure (mmHg)   
    Systolic 138 ± 17 136 ± 17 
    Diastolic 77 ± 9 77 ± 10 
Cholesterol (mg/dl)   
    Total 210 ± 31 207 ± 30 
    Triglycerides 109 (83–144) 112 (85–149) 
    HDL 54 ± 12 53 ± 14 
BMI (kg/m223.7 ± 3.4 24.2 ± 3.1 
eGFR (ml/min per 1.73 m2103 ± 24 101 ± 25 
AER (μg/min) 49 (34–97) 42 (29–74) 
Retinopathy (%) 83 84 
Antihypertensive treatment (%)   
    No/ACE-I or ARB/others 57/28/15 56/24/20 
    Lipid-lowering treatment (%) 22 21 
Current smoker (%) 32 42 
History of cardiovascular diseases (%) 15 20 
50% reductionNonreduction
n 93 123 
Sex (male/female) 56/37 85/38 
Age (years) 62 ± 8 61 ± 10 
Duration of diabetes (years) 14 ± 8 13 ± 9 
A1C (%) 7.5 ± 0.9 7.5 ± 1.0 
Blood pressure (mmHg)   
    Systolic 138 ± 17 136 ± 17 
    Diastolic 77 ± 9 77 ± 10 
Cholesterol (mg/dl)   
    Total 210 ± 31 207 ± 30 
    Triglycerides 109 (83–144) 112 (85–149) 
    HDL 54 ± 12 53 ± 14 
BMI (kg/m223.7 ± 3.4 24.2 ± 3.1 
eGFR (ml/min per 1.73 m2103 ± 24 101 ± 25 
AER (μg/min) 49 (34–97) 42 (29–74) 
Retinopathy (%) 83 84 
Antihypertensive treatment (%)   
    No/ACE-I or ARB/others 57/28/15 56/24/20 
    Lipid-lowering treatment (%) 22 21 
Current smoker (%) 32 42 
History of cardiovascular diseases (%) 15 20 

Data are means ± SD for normally distributed continuous variables or median (25th–75th interquartiles) for skewed continuous variables unless otherwise indicated. ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker.

Close Modal

or Create an Account

Close Modal
Close Modal